TY - JOUR
T1 - Neuroimmunological diseases
T2 - update
AU - Kira, Jun ichi
PY - 2008/6
Y1 - 2008/6
N2 - During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.
AB - During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.
UR - http://www.scopus.com/inward/record.url?scp=48049093969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48049093969&partnerID=8YFLogxK
M3 - Review article
C2 - 18540346
AN - SCOPUS:48049093969
SN - 0047-1852
VL - 66
SP - 1039
EP - 1048
JO - Nippon rinsho. Japanese journal of clinical medicine
JF - Nippon rinsho. Japanese journal of clinical medicine
IS - 6
ER -